Unfortunately for us, the criteria is a political document.
I'd like to think that they are looking at this from the angle that these alternative treatments need to be put to the test in order to show that they fail - but that's not really how it reads is it. I'm still bemused by homeopathy in general, my wife's GP offered her it the other day.
But if you don't try to carefully define the illness in the first place, then how can you investigate the correct patients when there are no known biological markers? If you investigate every type of fatigued patient on the planet, including depressive patients, then how can you achieve meaningful results?
I have PEM and cutting out those without it might help focus the research. That suits me. Which would be good. But we don't know that the absence of PEM means you are ME negative. Only that it's presence is specific to the disease, so it indicates a positive.
There are other ways to exclude other fatigue illnesses, though likely not as completely. If we did that, how many are left that don't have PEM? What's the split? Do these people look different in studies? (PEM aside)
I'd just hate to be one of those poor sods who ends up being dumped and all that means. Especially if fifty years later it turned out they do have the same disease after all, just a PEM-symptom-negative version for some reason.
But are we not agreed that there are no 'correct' patients here. Anyone who has disabling fatigue deserves investigation just as much.
Yes, we're all agreed on that.Anyone who has disabling fatigue deserves investigation just as much.
Erm, no, in a nutshell, I think it's safe to say that that's not the consensus on this forum.But are we not agreed that there are no 'correct' patients here.
For ME/CFS, there simply hasn't been any research. And the limited research that there has been has used the all-inclusive Fukuda, or Oxford.I suspect that a desire to stick to one set of criteria may be a major reason for missing interesting findings - because there is often an assumption that there will be a Gaussian population that can be analysed parametrically. Sticking to the same criteria for all questions is what drives unproductive me-too research in my view.
Yes, this was my objection to this charade from the beginning. They can't find any money to fund research but they can find $1M for this? A very good illustration of the hypocrisy of just wanting to "manage" us, not fund the research we need.CFSAC recomendation of October 2012 stated:
We could have saved a million dollars.
Yes, this is part of why I embrace the ICC. I've been sick with ME for almost 35 years. During the first 25 years I didn't have a lot of pain and I didn't have ataxia. Now those are two of my most troublesome symptoms. The only symptoms that have not changed much, both up and down, are PEM, the lack of energy and the lack of stamina. And now that I'm using medical cannabis, the lack of restful sleep is almost completely resolved, after suffering from that for about 34 years.Re leaving people out in the cold, don't forget that the ICC has an atypical category:
"Atypical myalgic encephalomyelitis: meets criteria for postexertional neuroimmune exhaustion but has a limit of two
less than required of the remaining criterial symptoms. Pain or sleep disturbance may be absent in rare cases."
I think this misses the whole point, yet the argument is raised time and time again, and is used to by some to deliberately confuse any attempts to refine CCC or ICC. If even in the short term some people are left out in the cold, in the longer term they will probably be better off.
Why? Because a better definition for a narrow cohort will focus research and lead to possible causes and treatments much earlier for the better defined cohort. So rather than all being left in the cold, at least some will receive benefit. However, if an agent or treatment is found, this can then be trialled on those which were left in the cold in the first place. The sooner we stop dithering about this, the quicker such a program can begin. I don't see any benefit in the argument whatsoever.
In fact finding an agent or treatment for an all inclusive defined group is probably impossible, or at least is many years away.
I think we should probably start a separate thread about this, as it's an important, complex and loaded issue that could lead to a prolonged off-topic discussion.
Yes, we're all agreed on that.
Erm, no, in a nutshell, I think it's safe to say that that's not the consensus on this forum.
I'll try to explain why...
The problem with "fatigue" is that it covers such a wide range of known and unknown illnesses.
For example, people with flu experience fatigue, someone with a gum infection might experience fatigue, people with depression experience fatigue, and people with MS experience fatigue, etc etc.
So, if you are selecting patients, by the symptom of fatigue alone, then I can't see how you could possibly ever get any meaningful research results.
Because if you selected 100 fatigued patients, you would probably have 100 different illnesses.
So, I think the broad consensus on this forum is that nothing will ever be understood about this illness (or these illnesses) if "fatigue" is the selection criteria in research.
So I think the consensus on this forum is that "ME" criteria should be used for research, at least to create a sub-group, even if it is a heterogeneous sub-group, because then at least there is an attempt to narrow down the nature of the illness from "any illness on the planet that involves fatigue". And it would help to filter out other (known) fatiguing illnesses that are undiagnosed.
In other words, by using "ME" criteria in research, there is an attempt to look at a pattern of symptoms, with some similarity between patients, other than the simple presence of fatigue.
Most of us agree that ME is not fatigue, but it is a specific pattern of symptoms, which includes specific symptoms other than fatigue.
I would assume that you get a pattern of illness or a pattern of symptoms in RA, other than the patient simply experiencing "pain" even if there are different types of RA? Would the simple presence of "pain" (any type of pain, anywhere in the body) be an adequate entry criteria for a study of RA?
For ME/CFS, there simply hasn't been any research. And the limited research that there has been has used the all-inclusive Fukuda, or Oxford.
Treatment should be based on lab results and symptoms. The disease label shouldn't be the only factor, or even the main factor.If you get cut out then you do not have the same disease label anymore, you have something else. When a treatment comes about and gets approved, it gets approved for those that were studied in the trials, not those that have now got some other disease and got excluded, maybe years ago, and since have continued to be exploited by the psychobabblers.
Treatment should be based on lab results and symptoms. The disease label shouldn't be the only factor, or even the main factor.
You're accustomed to your medical system failing you very badly. Based solely on having the ME/CFS label, treatment intended for your symptoms (regardless of disease) is withheld. This is a problem with the NHS taking a very inappropriate approach to treating patients in certain circumstances. The disease, or the label, or the symptoms are not the problem - the system is the problem, and the psychogenic theory is allowing that system to impose the lack of treatment.
There's this bizarre belief that only ME treatments can be used for ME patients, but that isn't even remotely true. It's the excuse for withholding treatment, but it's a blatant lie. Treatments resulting from ME-only research shouldn't result in those treatments being withheld from non-ME fatigue patients who have the same symptom treated in that research.
I have made this same point repeatedly. The problem is that the kind of testing and stratification requires more funding, and its typically not done. When its not done is when the problems arise. The only study that has had serious funding is the PACE trial, and their attempt to subgroup was ludicrous. Fukuda that was not using the Fukuda definition, and ME that was not using the London criteria ... how was this allowed to be even published?From what I have seen of available epidemiology a study that recruited on an non-selective basis from chronic fatigue sufferers in a defined population then you might have double or even five times as many cases but these can easily be stratified for features that are relevant to the specific study.
At the moment, criteria for unknowledgeable doctors says: "suspect CFS in a patient with fatigue [tiredness] lasting >6 months" with or without mostly vague add-on symptoms (depending on country/ criteria). Even the way PEM is described by NICE, for example, comes out vague.
This is a point I keep coming back to. A cluster is the best way to get a homogeneous patient cohort for research. There is one caveat though. You should not mix clusters, except perhaps in close temporal and geographic proximity, such as Incline Village and Londonville. There is no guarantee the the Incline Village cluster and the Royal Free Hospital cluster are the same, at least not until we have biomarkers.These outbreak clusters are those patients that clearly define a study group.